IMMUNOVANT INC (IMVT) Stock Fundamental Analysis

NASDAQ:IMVT • US45258J1025

25.94 USD
+0.3 (+1.17%)
Last: Feb 13, 2026, 09:33 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMVT. IMVT was compared to 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMVT as it has an excellent financial health rating, but there are worries on the profitability. IMVT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year IMVT has reported negative net income.
  • IMVT had a negative operating cash flow in the past year.
  • IMVT had negative earnings in each of the past 5 years.
  • In the past 5 years IMVT always reported negative operating cash flow.
IMVT Yearly Net Income VS EBIT VS OCF VS FCFIMVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • The Return On Assets of IMVT (-79.69%) is worse than 67.30% of its industry peers.
  • The Return On Equity of IMVT (-89.39%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.69%
ROE -89.39%
ROIC N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
IMVT Yearly ROA, ROE, ROICIMVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IMVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMVT Yearly Profit, Operating, Gross MarginsIMVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, IMVT has more shares outstanding
  • The number of shares outstanding for IMVT has been increased compared to 5 years ago.
  • IMVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMVT Yearly Shares OutstandingIMVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
IMVT Yearly Total Debt VS Total AssetsIMVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • IMVT has an Altman-Z score of 44.22. This indicates that IMVT is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 44.22, IMVT belongs to the top of the industry, outperforming 95.41% of the companies in the same industry.
  • There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 44.22
ROIC/WACCN/A
WACCN/A
IMVT Yearly LT Debt VS Equity VS FCFIMVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 9.07 indicates that IMVT has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 9.07, IMVT is in the better half of the industry, outperforming 79.16% of the companies in the same industry.
  • A Quick Ratio of 9.07 indicates that IMVT has no problem at all paying its short term obligations.
  • IMVT's Quick ratio of 9.07 is fine compared to the rest of the industry. IMVT outperforms 79.16% of its industry peers.
Industry RankSector Rank
Current Ratio 9.07
Quick Ratio 9.07
IMVT Yearly Current Assets VS Current LiabilitesIMVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • IMVT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.67%.
EPS 1Y (TTM)-2.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • IMVT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.00% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.35%
EPS Next 2Y-4.55%
EPS Next 3Y2.17%
EPS Next 5Y26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMVT Yearly Revenue VS EstimatesIMVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B
IMVT Yearly EPS VS EstimatesIMVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • IMVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMVT Price Earnings VS Forward Price EarningsIMVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMVT Per share dataIMVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.55%
EPS Next 3Y2.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IMVT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMMUNOVANT INC

NASDAQ:IMVT (2/13/2026, 9:33:08 AM)

25.94

+0.3 (+1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)05-27
Inst Owners47.26%
Inst Owner Change0.08%
Ins Owners1.29%
Ins Owner Change14%
Market Cap5.28B
Revenue(TTM)N/A
Net Income(TTM)-464.56M
Analysts83.48
Price Target40.26 (55.2%)
Short Float %22.91%
Short Ratio10.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.9%
Min EPS beat(2)-7.99%
Max EPS beat(2)0.2%
EPS beat(4)3
Avg EPS beat(4)1.3%
Min EPS beat(4)-7.99%
Max EPS beat(4)12.44%
EPS beat(8)4
Avg EPS beat(8)-3.65%
EPS beat(12)5
Avg EPS beat(12)-6.43%
EPS beat(16)6
Avg EPS beat(16)-5.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.94%
PT rev (3m)4.28%
EPS NQ rev (1m)0.15%
EPS NQ rev (3m)1.41%
EPS NY rev (1m)0.23%
EPS NY rev (3m)0.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.16
P/tB 10.16
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-3
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS0
BVpS2.55
TBVpS2.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.69%
ROE -89.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.07
Quick Ratio 9.07
Altman-Z 44.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)154.15%
Cap/Depr(5y)190.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.74%
EPS Next Y-8.35%
EPS Next 2Y-4.55%
EPS Next 3Y2.17%
EPS Next 5Y26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.74%
EBIT Next 3Y-7.34%
EBIT Next 5YN/A
FCF growth 1Y-105.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.52%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOVANT INC / IMVT FAQ

Can you provide the ChartMill fundamental rating for IMMUNOVANT INC?

ChartMill assigns a fundamental rating of 3 / 10 to IMVT.


What is the valuation status of IMMUNOVANT INC (IMVT) stock?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNOVANT INC (IMVT). This can be considered as Overvalued.


What is the profitability of IMVT stock?

IMMUNOVANT INC (IMVT) has a profitability rating of 0 / 10.


What is the expected EPS growth for IMMUNOVANT INC (IMVT) stock?

The Earnings per Share (EPS) of IMMUNOVANT INC (IMVT) is expected to decline by -8.35% in the next year.